← Leaderboards
Christopher I Li
Fred Hutchinson Cancer Research Center
$36,171,442
Attributed
$62,724,465
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$71,150,887 · 19
By mechanism
U01$26,969,283 · 3
R01$24,340,430 · 6
P50$7,295,156 · 4
U24$5,734,923 · 1
P20$4,534,653 · 2
T32$1,345,793 · 1
Top collaborators
- Cornelia M Ulrich21 shared
- Charles Drescher7 shared
- Paul D Lampe7 shared
- Jane C. Figueiredo6 shared
- Ulrike Peters6 shared
- Erin Siegel6 shared
- Timothy K Thomas6 shared
- Yingye Zheng6 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Catherine M. Tangen$27,475,187
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanMalignant NeoplasmsColorectal CancerDiagnosisEpidemiologyMalignant Breast NeoplasmSamplingLeadDesignBaseBiological MarkersUnited StatesValidationTumor TissueRisk FactorsPerformanceResourcesMortalityMonitorTumorCohortCharacteristicsIncidenceFollow-Up
Grant awards (104)
Translational Research Program in Colorectal Cancer Disparities$2,455,587
P50 · FY2025 · CA
Fred Hutchinson Breast Cancer Clinical Validation Center$858,468
U01 · FY2025 · CA · contact PI
Contributing Factors and Consequences of Cancer Health Disparities$435,600
T32 · FY2025 · CA
Project 2: Discovery and validation of novel molecular and immune predictors of colorectal cancer and mortality and response to treatment across patient populations groups$267,212
P50 · FY2025 · CA · contact PI
Career Enhancement Program$88,000
P50 · FY2025 · CA · contact PI
Translational Research Program in Cancer Differences across Populations$2,575,782
P50 · FY2024 · CA
Fred Hutchinson Breast Cancer Clinical Validation Center$1,047,995
U01 · FY2024 · CA · contact PI
Contributing Factors and Consequences of Cancer Health Disparities$506,977
T32 · FY2024 · CA
Project 2: Discovery and validation of novel molecular and immune predictors of colorectal cancer mortality and response to treatment in racially and ethnically diverse patient populations$286,521
P50 · FY2024 · CA · contact PI
Career Enhancement Program$84,480
P50 · FY2024 · CA · contact PI
Fred Hutchinson Breast Cancer Clinical Validation Center$1,060,017
U01 · FY2023 · CA · contact PI
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$642,698
U24 · FY2023 · CA · contact PI
Contributing Factors and Consequences of Cancer Health Disparities$403,216
T32 · FY2023 · CA
Translational Research Program in Colorectal Cancer Disparities$1,081,347
P20 · FY2022 · CA
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence$868,657
R01 · FY2022 · CA
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$822,171
U24 · FY2022 · CA · contact PI
Fred Hutchinson Breast Cancer Clinical Validation Center$807,303
U01 · FY2022 · CA · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$471,680
U01 · FY2022 · ES
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity$411,154
P20 · FY2022 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,936,657
U01 · FY2021 · CA
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence$1,034,169
R01 · FY2021 · CA
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$743,093
U24 · FY2021 · CA · contact PI
Translational Research Program in Colorectal Cancer Disparities$703,121
P20 · FY2021 · CA
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$418,953
U01 · FY2021 · CA · contact PI
Translational Research Program in Colorectal Cancer Disparities$406,634
P20 · FY2021 · CA
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$319,373
U01 · FY2021 · ES
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity$271,058
P20 · FY2021 · CA · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$152,307
U01 · FY2021 · ES
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity$119,285
P20 · FY2021 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,967,702
U01 · FY2020 · CA
Translational Research Program in Colorectal Cancer Disparities$1,203,951
P20 · FY2020 · CA
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$1,156,938
U24 · FY2020 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$836,410
U01 · FY2020 · CA · contact PI
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence$555,888
R01 · FY2020 · CA
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$471,680
U01 · FY2020 · ES
Discovery and verification of novel biomarkers of colorectal cancer recurrence$420,049
R01 · FY2020 · CA · contact PI
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity$338,103
P20 · FY2020 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$166,534
U01 · FY2020 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,717,150
U01 · FY2019 · CA
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$1,152,820
U24 · FY2019 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$779,890
U01 · FY2019 · CA · contact PI
Discovery and verification of novel biomarkers of colorectal cancer recurrence$608,367
R01 · FY2019 · CA · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$471,680
U01 · FY2019 · ES
Discovery and verification of novel biomarkers of colorectal cancer recurrence$78,749
R01 · FY2019 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,745,632
U01 · FY2018 · CA
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)$1,217,203
U24 · FY2018 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$1,085,901
U01 · FY2018 · CA · contact PI
Discovery and verification of novel biomarkers of colorectal cancer recurrence$1,061,207
R01 · FY2018 · CA · contact PI
Epidemiology of the four most frequent cancers following breast cancer$928,970
R01 · FY2018 · CA
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence$890,636
R01 · FY2018 · CA
PREcision Disease preventIon via somatiC muTagenesis enumeratION (PREDICTION)$471,680
U01 · FY2018 · ES
Discovery and verification of novel biomarkers of colorectal cancer recurrence$76,166
R01 · FY2018 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,839,122
U01 · FY2017 · CA
Discovery and verification of novel biomarkers of colorectal cancer recurrence$1,061,342
R01 · FY2017 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$972,870
U01 · FY2017 · CA · contact PI
Epidemiology of the four most frequent cancers following breast cancer$956,771
R01 · FY2017 · CA
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence$507,585
R01 · FY2017 · CA
Discovery and verification of novel biomarkers of colorectal cancer recurrence$48,248
R01 · FY2017 · CA · contact PI
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study$1,862,336
U01 · FY2016 · CA
Discovery and verification of novel biomarkers of colorectal cancer recurrence$1,042,128
R01 · FY2016 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$1,011,430
U01 · FY2016 · CA · contact PI
Epidemiology of the four most frequent cancers following breast cancer$935,354
R01 · FY2016 · CA
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$179,050
P50 · FY2016 · CA · contact PI
Discovery and verification of novel biomarkers of colorectal cancer recurrence$98,960
R01 · FY2016 · CA · contact PI
Discovery and verification of novel biomarkers of colorectal cancer recurrence$1,084,138
R01 · FY2015 · CA · contact PI
Epidemiology of the four most frequent cancers following breast cancer$952,389
R01 · FY2015 · CA
Breast and Ovary Cancer Clinical Validation Center$93,620
U01 · FY2015 · CA · contact PI
Epidemiology of the four most frequent cancers following breast cancer$932,958
R01 · FY2014 · CA
Breast and Ovary Cancer Clinical Validation Center$725,717
U01 · FY2014 · CA · contact PI
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors$554,629
R01 · FY2014 · CA · contact PI
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$272,139
P50 · FY2014 · CA · contact PI
Breast and Ovary Cancer Clinical Validation Center$881,335
U01 · FY2013 · CA · contact PI
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors$632,199
R01 · FY2013 · CA · contact PI
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$272,680
P50 · FY2013 · CA · contact PI
Breast and Ovary Cancer Clinical Validation Center$165,129
U01 · FY2013 · CA · contact PI
Breast and Ovary Cancer Clinical Validation Center$973,064
U01 · FY2012 · CA · contact PI
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors$710,042
R01 · FY2012 · CA · contact PI
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$278,527
P50 · FY2012 · CA · contact PI
Breast and Ovary Cancer Clinical Validation Center$798,082
U01 · FY2011 · CA · contact PI
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors$709,424
R01 · FY2011 · CA · contact PI
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$246,731
P50 · FY2011 · CA · contact PI
Breast and Ovary Cancer Clinical Validation Center$859,566
U01 · FY2010 · CA · contact PI
Risk Factors for Second Primary Breast Cancer Among DCIS Survivors$600,677
R01 · FY2010 · CA · contact PI
RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVEREXPRESSING BREAST CANCER AMONG HI..$288,447
P50 · FY2010 · CA · contact PI
Migraine, Migraine Medication Use, and Risk of Breast Cancer$88,000
R03 · FY2010 · CA · contact PI
Depo-Provera and Breast Cancer: Epidemiology/Pathology$630,109
R01 · FY2009 · CA · contact PI
Depo-Provera and Breast Cancer: Epidemiology/Pathology$349,714
R01 · FY2009 · CA · contact PI
Migraine, Migraine Medication Use, and Risk of Breast Cancer$88,000
R03 · FY2009 · CA · contact PI
Depo-Provera and Breast Cancer: Epidemiology/Pathology$640,635
R01 · FY2008 · CA · contact PI
Protein Biomarkers of Cancer Risk in Older Persons$443,168
R01 · FY2008 · CA · contact PI
Depo-Provera and Breast Cancer: Epidemiology/Pathology$640,398
R01 · FY2007 · CA · contact PI
Tamoxifen & Second Breast Cancer: Epidemiology/Pathology$566,239
R01 · FY2007 · CA · contact PI
Protein Biomarkers of Cancer Risk in Older Persons$306,408
R01 · FY2007 · CA · contact PI
c-erbB-2 and Risk of Contralateral Breast Cancer$155,250
K01 · FY2007 · CA · contact PI
Tamoxifen & Second Breast Cancer: Epidemiology/Pathology$713,769
R01 · FY2006 · CA · contact PI
Depo-Provera and Breast Cancer: Epidemiology/Pathology$658,665
R01 · FY2006 · CA · contact PI
Protein Biomarkers of Cancer Risk in Older Persons$318,151
R01 · FY2006 · CA · contact PI
c-erbB-2 and Risk of Contralateral Breast Cancer$155,250
K01 · FY2006 · CA · contact PI
Tamoxifen &Second Breast Cancer: Epidemiology/Pathology$697,872
R01 · FY2005 · CA
Depo-Provera and Breast Cancer: Epidemiology/Pathology$674,271
R01 · FY2005 · CA
Protein Biomarkers of Cancer Risk in Older Persons$351,329
R01 · FY2005 · CA
c-erbB-2 and Risk of Contralateral Breast Cancer$155,250
K01 · FY2005 · CA
c-erbB-2 and Risk of Contralateral Breast Cancer$155,250
K01 · FY2004 · CA
c-erbB-2 and Risk of Contralateral Breast Cancer$133,649
K01 · FY2003 · CA